Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Fruquintinib in ARID1A-mutated MSS mCRC
NCT05690035Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Conditions
- metastatic colorectal cancer (mCRC)
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 3 years. Planned start Jul 2025; status: withdrawn.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Tislelizumab + Fruquintinib
Combination therapy with Tislelizumab and Fruquintinib.
03
Who it enrols
Patients with ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have failed at least 2 lines of standard chemotherapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Overall Survival
Disease Control Rate
Incidence of Treatment-Emergent Adverse Events
Beyond the preview
Go deeper on NCT05690035.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690035.